Edward J Dulac III has sold stock and made no open-market buys since Aug 2021

Edward J. Dulac III is an accomplished finance executive in the biotechnology sector, serving as Executive Vice President, Chief Financial Officer, and Treasurer at Intellia Therapeutics, Inc. (NASDAQ: NTLA) since July 22, 2024.( With over 20 years of experience, he previously held the CFO role at Fate Therapeutics from 2020 to 2024, where he led finance, capital strategy, and operations for clinical-stage cell therapies, and served as Vice President of Business Development & Strategy at Celgene (now Bristol Myers Squibb).( Earlier in his career, Dulac worked as a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers, and in corporate finance at Pfizer.(

Dulac holds a Bachelor of Science in Pharmacy from the University of Pittsburgh and an MBA from the Indiana University Kelley School of Business.( At Intellia, a pioneer in CRISPR-based gene editing therapies, he has managed financial operations amid key achievements like Phase 3 trial initiations and maintaining a cash runway through H1 2027.( In July 2025, he sold 7,462 shares at $14.02 each to cover tax obligations on RSU vesting, retaining 106,062 shares.(

Written by Perplexity from public sources.